Merck and Kelun drug cuts death risk in advanced endometrial cancer
โฎ BeforePatients with advanced endometrial cancer faced a higher risk of death on existing treatments.
โ
NowIn a Phase 3 trial, a targeted drug cut that risk by one-third.
In short
- A Phase 3 trial tested a targeted drug developed by Merck and China's Kelun-Biotech.
- The drug cut the risk of death by one-third in patients with advanced endometrial cancer.
- The source reports this as a trial result; the wider approval status is not stated.
Why it's good news
The trial measured a fall of about one-third in the risk of death for patients with advanced endometrial cancer. That is a large effect for a cancer where options can run short. The result comes from a Phase 3 trial, the stage that comes before wider approval, so the benefit still needs to be confirmed in routine care.
Advertisement
From STAT
A Phase 3 trial of a targeted drug developed by Merck and Chinaโs Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer.
Ask this story
More like this
Advertisement